Changes in Beneficial Ownership · 4
Roivant Sciences Ltd.
ROIVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-16
- Issuer
- Roivant Sciences Ltd.
- Issuer CIK
- 0001635088
- Trading symbol
- ROIV
Reporting owner 1
- Name
- MANCHESTER KEITH S
- Reporting owner CIK
- 0001244828
- Relationship
- Director
- Address
- C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, UNITED KINGDOM, X0, SW1H 0DB
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | 2026-11-16 | S · Form 4 | 79,461 | D | 39.17 | 13,609,705 | I[F1] | Held by QVT Financial Investment Cayman Ltd. |
| Common Shares | 2026-11-16 | S · Form 4 | 550,280 | D | 39.17 | 1,042,200 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd |
| Common Shares | 2026-11-16 | S · Form 4 | 18,927 | D | 38.99 | 13,590,778 | I[F1] | Held by QVT Financial Investment Cayman Ltd. |
| Common Shares | 2026-11-16 | S · Form 4 | 131,073 | D | 38.99 | 911,127 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd |
| Common Shares | 2026-11-17 | J · Form 4[F2] | 2,635,169 | D | 0.00 | 5,806,259 | I[F1] | Held by QVT Deferred Compensation Holdings Ltd. |
| Common Shares | 2026-11-17 | J · Form 4[F2] | 15,969 | D | 0.00 | 13,574,809 | I[F1] | Held by QVT Financial Investment Cayman Ltd. |
| Common Shares | 2026-11-17 | J · Form 4[F2] | 385,620 | D | 0.00 | 525,507 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd |
| Common Shares | 2026-11-17 | S · Form 4 | 75,716 | D | 38.24 | 13,499,093 | I[F1] | Held by QVT Financial Investment Cayman Ltd. |
| Common Shares | 2026-11-17 | S · Form 4 | 525,507 | D | 38.24 | 0 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd |
| Common Shares | 2026-11-17 | S · Form 4 | 798 | D | 38.24 | 5,805,461 | I[F1] | Held by QVT Deferred Compensation Holdings Ltd. |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
- J · Form 4
- Other acquisition or disposition; see explanation
Footnotes
- F1
- The reporting person is a shareholder of each of QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
Signature 1
- Signed
- /s/ Keith Manchester
- Date
- 2026-11-18
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.